| 1 | 10061 | LAO-PA015 | ETCTN | Solid Tumor | Active | A Phase 1 Study of Pembrolizumab (MK-3475) in Combination with Recombinant Interleukin-12 in Patients with Solid Tumors | I | 21/36 | N/A | INTERVENTION |
| 2 | 10144 | LAO-NCI | ETCTN | Endocrine Cancer;Kidney Cancer;Male Reproductive System Cancer;Urothelial/ Bladder Cancer | Active | A Phase II Study of Olaparib (AZD2281) in Patients with Metastatic/Advanced Urothelial Carcinoma with DNA-Repair Defects | II | 4/60 | 5 | SCREENING, INTERVENTION |
| 3 | 10273 | LAO-CA043 | ETCTN | Leukemia | Active | A Phase I Study of M3814 in Combination with MEC in Patients with Relapsed or Refractory Acute Myeloid Leukemia | I | 14/48 | N/A | INTERVENTION |
| 4 | 10301 | LAO-CT018 | ETCTN | Male Reproductive System Cancer | Active | A Phase I and Randomized Phase II Trial of Radium-223 Dichloride, M3814, & Avelumab in Advanced Metastatic Castrate-Resistant Prostate Cancer (mCRPC) | I/II | 9/24 | N/A | INTERVENTION |
| 5 | 10330 | LAO-CT018 | ETCTN | Bone Cancer | Temporarily Closed to Accrual | A Phase 2 Study of Belinostat and SGI-110 (Guadecitabine) or ASTX727 for the Treatment of Unresectable and Metastatic Conventional Chondrosarcoma | II | 19/32 | N/A | INTERVENTION |
| 6 | 10387 | EDDO-NY313 | ETCTN | AIDS-related Malignancy and Condition;Solid Tumor | Active | Pilot Trial of Nivolumab Plus Cabozantinib for Advanced Solid Tumors in Patients with HIV Infection | I | 2/18 | N/A | INTERVENTION |
| 7 | 10404 | LAO-CA043 | ETCTN | Solid Tumor;Urothelial/ Bladder Cancer | Temporarily Closed to Accrual | A Phase 1 Trial of the ATR Inhibitor BAY 1895344 in Combination with Cisplatin and with Cisplatin Plus Gemcitabine in Advanced Solid Tumors with an Emphasis on Urothelial Carcinoma | I | 7/74 | N/A | INTERVENTION |
| 8 | 10406 | LAO-PA015 | ETCTN | Gastrointestinal Cancer | Active | Phase I/Ib Trial of ATR Inhibitor BAY 1895344 in Combination with FOLFIRI in GI Malignancies with a Focus on Metastatic Colorectal and Gastric/Gastroesophageal Cancers | I | 6/90 | N/A | INTERVENTION |
| 9 | 10504 | LAO-NCI | ETCTN | Soft Tissue Cancer/Sarcoma | Active | A Randomized Phase 2 Study of Atezolizumab with or Without Selinexor in Alveolar Soft Part Sarcoma (AXIOM) | II | 0/77 | N/A | INTERVENTION |
| 10 | 10507 | LAO-MA036 | ETCTN | Miscellaneous and Metastatic Cancer | Active | A Phase 1/2 Study of the Bromodomain Inhibitor ZEN003694 in Combination with Etoposide/Platinum in Patients with NUT Carcinoma | I/II | 0/18 | N/A | INTERVENTION |
| 11 | 9892 | LAO-PA015 | ETCTN | AIDS-related Malignancy and Condition;Female Reproductive System Cancer | Active | Phase I Dose-Escalation Bioavailability Study of Oral Triapine in Combination with Concurrent Chemoradiation for Locally Advanced Cervical Cancer (LACC) and Vaginal Cancer | I | 11/76 | N/A | INTERVENTION |
| 12 | 9938 | LAO-PA015 | ETCTN | Solid Tumor | Active | Phase I Clinical Trial of M6620 (VX-970, Berzosertib) in Combination with the Topoisomerase I Inhibitor Irinotecan in Patients with Advanced Solid Tumors | I | 64/66 | N/A | INTERVENTION |
| 13 | A021806 | ALLIANCE | NCTN | Gastrointestinal Cancer | Active | A Phase III Trial of Perioperative Versus Adjuvant Chemotherapy for Resectable Pancreatic Cancer | III | 107/352 | N/A | INTERVENTION |
| 14 | A041703 | ALLIANCE | NCTN | Leukemia | Active | A Phase II Study of Inotuzumab Ozogamicin Followed by Blinatumomab for Ph-Negative, CD22-Positive B-Lineage Acute Lymphoblastic Leukemia in Newly Diagnosed Older Adults or Adults with Relapsed or Refractory Disease | II | 47/64 | N/A | INTERVENTION |
| 15 | A051902 | ALLIANCE | NCTN | Lymphoma | Active | A Randomized Phase II Study of CHO(E)P vs CC-486-CHO(E)P vs Duvelisib-CHO(E)P in Previously Untreated CD30 Negative Peripheral T-Cell Lymphomas | II | 7/182 | N/A | INTERVENTION |
| 16 | A071401 | ALLIANCE | NCTN | CNS Cancer (Primary tumor) | Active | Phase II Trial of SMO/ AKT/ NF2/CDK Inhibitors in Progressive Meningiomas with SMO/ AKT/ NF2/CDK Pathway Mutations | II | 57/124 | 370 | SCREENING, INTERVENTION |
| 17 | A171901 | ALLIANCE | NCORP | Lung, Mediastinal, and Pleural Cancer | Active | Older Non-Small Cell Lung Cancer Patients (>/= 70 Years of Age) Treated with First-Line MK-3475 (Pembrolizumab)+/- Chemotherapy (Oncologist's/Patient's Choice) | II | 61/100 | N/A | INTERVENTION |
| 18 | A211801 | ALLIANCE | NCORP | N/A | Active | BRCA-P: A Randomized, Double-Blind, Placebo-Controlled, Multi-Center, International Phase 3 Study to determine the Preventive Effect of Denosumab on Breast Cancer in Women carrying a BRCA1 Germline Mutation | III | 0/300 | N/A | INTERVENTION |
| 19 | A221702 | ALLIANCE | NCORP | Breast Cancer | Active | ARM: Axillary Reverse Mapping - A Prospective Trial to Study Rates of Lymphedema and Regional Recurrence after Sentinel Lymph Node Biopsy and Sentinel Lymph Node Biopsy Followed by Axillary Lymph Node Dissection with and without Axillary Reverse Mapping | III | 500/516 | N/A | INTERVENTION |
| 20 | DCP-001 | DCP | NCORP | Hematopoietic Neoplasm (excluding Leukemia, Lymphoma and Myeloma);Solid Tumor | Active | Use of a Clinical Trial Screening Tool to Address Cancer Health Disparities in the NCI Community Oncology Research Program (NCORP) | Other | N/A | N/A | OTHER |
| 21 | EA1181 | ECOG-ACRIN | NCTN | Breast Cancer | Active | EA1181 (CompassHER2-pCR): Preoperative THP and Postoperative HP in Patients Who Achieve a Pathologic Complete Response Part 1 Component of: The CompassHER2 Trials (COMprehensive Use of Pathologic Response ASSessment to Optimize Therapy in HER2-Positive Breast Cancer) | II | 1320/2156 | N/A | INTERVENTION |
| 22 | EA2192 | ECOG-ACRIN | NCTN | Gastrointestinal Cancer | Active | APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Curative Intent Therapy in Patients with Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation | II | 20/152 | N/A | INTERVENTION |
| 23 | EA5163 | ECOG-ACRIN | NCTN | Lung, Mediastinal, and Pleural Cancer | Active | EA5163/S1709 INSIGNA : A Randomized, Phase III Study of Firstline Immunotherapy Alone or in Combination with Chemotherapy in Induction/Maintenance or Postprogression in Advanced Nonsquamous Non-Small Cell Lung Cancer (NSCLC) with Immunobiomarker SIGNature-Driven Analysis | III | 420/846 | N/A | INTERVENTION |
| 24 | EA6141 | ECOG-ACRIN | NCTN | Skin Cancer | Active | Randomized Phase II/III Study of Nivolumab Plus Ipilimumab Plus Sargramostim Versus Nivolumab Plus Ipilimumab in Patients with Unresectable Stage III or Stage IV Melanoma | II/III | 336/600 | N/A | INTERVENTION |
| 25 | EA8134 | ECOG-ACRIN | NCTN | Male Reproductive System Cancer | Active | InPACT- International Penile Advanced Cancer Trial (International Rare Cancers Initiative Study) | III | 51/200 | N/A | INTERVENTION |
| 26 | EAA173 | ECOG-ACRIN | NCTN | Myeloma | Active | Daratumumab to Enhance Therapeutic Effectiveness of Revlimid in Smoldering Myeloma (DETER-SMM) | III | 105/288 | N/A | INTERVENTION |
| 27 | NRG-BR005 | NRG | NCTN | Breast Cancer | Temporarily Closed to Accrual | A Phase II Trial Assessing the Accuracy of Tumor Bed Biopsies in Predicting Pathologic Response in Patients with Clinical/Radiologic Complete Response After Neoadjuvant Chemotherapy in Order to Explore the Feasibility of Breast Conserving Treatment Without Surgery | II | 105/175 | N/A | INTERVENTION |
| 28 | NRG-GY014 | NRG | NCTN | Female Reproductive System Cancer | Active | A Phase II Study of Tazemetostat (EPZ-6438) in Recurrent or Persistent Endometrioid or Clear Cell Carcinoma of the Ovary, and Recurrent or Persistent Endometrioid Endometrial Adenocarcinoma | II | 57/63 | N/A | INTERVENTION |
| 29 | NRG-GY020 | NRG | NCTN | Female Reproductive System Cancer | Active | A Phase III Randomized Trial of Radiation +/- Pembrolizumab (MK-3475) for Newly Diagnosed Early Stage High Intermediate Risk Mismatch Repair Deficient (dMMR) Endometrioid Endometrial Cancer | III | 131/168 | N/A | INTERVENTION |
| 30 | NRG-GY022 | NRG | NCTN | Solid Tumor | Active | Assessment of Carboplatin Clearance Predictors: A PK Study on NCI-Sponsored Clinical Trials or Standard of Care Treatments Using Carboplatin | I | 221/250 | N/A | INTERVENTION |
| 31 | PBTC-051 | PBTC | MISCELLANEOUS | CNS Cancer (Primary tumor) | Active | Phase I Study to Evaluate the Safety and Tolerability of the CD40 Agonistic Monoclonal Antibody APX005M in Pediatric Subjects with Recurrent/Refractory Brain Tumors and Newly Diagnosed Brain Stem Glioma | I | 28/45 | N/A | INTERVENTION |
| 32 | S0820 | SWOG | NCORP | Gastrointestinal Cancer | Active | A Double Blind Placebo-Controlled Trial of Eflornithine and Sulindac to Prevent Recurrence of High Risk Adenomas and Second Primary Colorectal Cancers in Patients with Stage 0-III Colon or Rectal Cancer, Phase III- Preventing Adenomas of the Colon with Eflornithine and Sulindac (PACES) | III | 334/491 | N/A | INTERVENTION |
| 33 | S1501 | SWOG | NCORP | Breast Cancer | Active | Prospective Evaluation of Carvedilol in Prevention of Cardiac Toxicity in Patients with Metastatic HER-2+ Breast Cancer, Phase III | III | 271/817 | 289 | SCREENING, INTERVENTION |
| 34 | S1712 | SWOG | NCTN | Leukemia | Active | A Randomized Phase II Study of Ruxolitinib (NSC-752295) in Combination with BCR-ABL Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia (CML) Patients with Molecular Evidence of Disease | II | 76/84 | N/A | INTERVENTION |
| 35 | S1905 | SWOG | NCTN | Leukemia;Lymphoma | Temporarily Closed to Accrual | A Phase I/II Study of AKR1C3-Activated Prodrug OBI-3424 (OBI-3424) In Patients with Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia (T-ALL)/T-Cell Lymphoblastic Lymphoma (T-LBL) | I/II | 10/64 | N/A | INTERVENTION |
| 36 | S1914 | SWOG | NCTN | Lung, Mediastinal, and Pleural Cancer | Active | A Randomized Phase III Trial of Induction/Consolidation Atezolizumab (NSC #783608) + SBRT Versus SBRT Alone in High Risk, Early Stage NSCLC | III | 102/480 | N/A | INTERVENTION |
| 37 | S1933 | SWOG | NCTN | Lung, Mediastinal, and Pleural Cancer | Active | A Pilot Study of Hypofractionated Radiotherapy Followed by Atezolizumab Consolidation in Stage II or III NSCLC Patients with Borderline Performance Status | II | 22/47 | N/A | INTERVENTION |
| 38 | S1937 | SWOG | NCTN | Urothelial/ Bladder Cancer | Active | A Phase III Randomized Trial of Eribulin (NSC #707389) with or Without Gemcitabine Versus Standard of Care (Physician's Choice) for Treatment of Metastatic Urothelial Carcinoma Refractory to, or Ineligible for, Anti PD1/PDL1 Therapy | III | 9/465 | N/A | INTERVENTION |
| 39 | S2005 | SWOG | NCTN | Lymphoma | Temporarily Closed to Accrual | A Phase II Randomized Study of Ibrutinib and Rituximab with or Without Venetoclax in Previously Untreated Waldenström's Macroglobulinemia (WM) / Lymphoplasmacytic Lymphoma (LPL) | II | 1/71 | N/A | INTERVENTION |
| 40 | S2012 | SWOG | NCTN | Endocrine Cancer | Active | Randomized Phase II/III Trial of First Line Platinum/Etoposide with or Without Atezolizumab (NSC#783608) in Patients with Poorly Differentiated Extrapulmonary Small Cell Neuroendocrine Carcinomas (NEC) | II/III | 0/189 | N/A | INTERVENTION |
| 41 | S2013 | SWOG | NCORP | N/A | Active | Immune Checkpoint Inhibitor Toxicity (I-CHECKIT): A Prospective Observational Study | Other | N/A | N/A | OTHER |
| 42 | 10020 | LAO-CT018 | ETCTN | Breast Cancer | Temporarily Closed to Accrual | A Phase II Open-Label, Randomized Study of PARP Inhibition (Olaparib) Either Alone or in Combination with Anti-PD-L1 Therapy (Atezolizumab; MPDL3280A) in Homologous DNA Repair (HDR) Deficient, Locally Advanced or Metastatic Non-HER2-Positive Breast Cancer | II | 93/94 | N/A | INTERVENTION |
| 43 | 10026 | LAO-MA036 | ETCTN | Leukemia | Active | A Phase 1 Study of Ipilimumab in Combination with Decitabine in Relapsed or Refractory Myelodysplastic Syndrome/Acute Myeloid Leukemia | I | 54/48 | N/A | INTERVENTION |
| 44 | 10076 | LAO-TX035 | ETCTN | Myeloma | Active | A Phase 1 Dose-Escalation and Exploratory Dose Expansion Study of KRT-232 (AMG 232) in Combination with Carfilzomib, Lenalidomide, and Dexamethasone in Relapsed and/or Refractory Myeloma | I | 24/40 | N/A | INTERVENTION |
| 45 | 10184 | LAO-NCI | ETCTN | Head and Neck Cancer | Active | Birinapant and Intensity Modulated Re-Irradiation Therapy (IMRRT) for Locoregionally Recurrent Head and Neck Squamous Cell Carcinoma (HNSCC) | I | 5/34 | N/A | INTERVENTION |
| 46 | 10208 | LAO-11030 | ETCTN | Gastrointestinal Cancer | Active | A Phase I Study of Anetumab Ravtansine in Combination with Either Anti-PD-1 Antibody, or Anti-CTLA4 and Anti-PD-1 Antibodies or Anti-PD-1 Antibody and Gemcitabine in Mesothelin-Positive Advanced Pancreatic Adenocarcinoma | I/II | 33/74 | 377 | SCREENING, INTERVENTION |
| 47 | 10214 | LAO-MD017 | ETCTN | Gastrointestinal Cancer;Skin Cancer;Solid Tumor | Temporarily Closed to Accrual | Immune Checkpoint Blockade for Kidney Transplant Recipients with Selected Unresectable or Metastatic Cancers | I | 12/16 | N/A | INTERVENTION |
| 48 | 10272 | NCICCR | MISCELLANEOUS | Male Reproductive System Cancer | Active | A Phase II Multi-Institutional Trial to Evaluate Prostate Specific Membrane Antigen (PSMA)-Based PET Imaging of High Risk Prostate Cancer | II | 185/200 | N/A | INTERVENTION |
| 49 | 10296 | LAO-TX035 | ETCTN | Breast Cancer | Active | Phase Ib/II Trial of Copanlisib in Combination with Trastuzumab and Pertuzumab After Induction Treatment of HER2 Positive (HER2+) Metastatic Breast Cancer (MBC) with PIK3CA Mutation or PTEN Mutation | I/II | 2/12 | N/A | INTERVENTION |
| 50 | 10327 | LAO-CA043 | ETCTN | Lung, Mediastinal, and Pleural Cancer | Temporarily Closed to Accrual | A Phase I Trial of MLN0128 (Sapanisertib) and Telaglenastat (CB-839) HCL in Advanced NSCLC Patients | I | 13/85 | N/A | INTERVENTION |